Developing Evidence to Inform Regulatory Policy on Nicotine Content in E-Liquids
Launched by ROCHESTER INSTITUTE OF TECHNOLOGY · Sep 28, 2024
Trial Information
Current as of July 24, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age 21 yrs or older
- • Pod-style or pen-style users, not adjustable for power or airflow, nicotine greater than 0 mg/mL
- • Current everyday users
- • Use history of at least 30 days
- • No current use of combustible tobacco product, or nicotine replacement therapy
- • CO less than 6 ppm at intake
- • No plans to quit tobacco use in the next 30 days
- Exclusion Criteria:
- • History of acute or chronic asthma
- • Previous diagnosis of cancer
- • Other chronic medical conditions
- • Use of chronic prescription medications
- • Pneumonia in prior six weeks
- • Upper respiratory tract infection or other febrile illness in previous 2 weeks
- • On antioxidants or anti-inflammatory therapy
- • Pregnant women or women who intend to become pregnant
About Rochester Institute Of Technology
The Rochester Institute of Technology (RIT) is a leading institution dedicated to advancing innovation and research in various fields, including healthcare and technology. With a strong emphasis on interdisciplinary collaboration, RIT conducts clinical trials that leverage its expertise in applied science, engineering, and health informatics. The institute aims to translate research findings into practical applications that improve patient outcomes and enhance healthcare delivery. Committed to ethical standards and rigorous methodologies, RIT's clinical trials contribute to the advancement of medical knowledge and the development of novel therapeutic strategies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Rochester, New York, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported